77 related articles for article (PubMed ID: 9022749)
1. Molecular origins of selectivity in the interaction of amsacrine-4-carboxamide with GC-rich sequences in DNA.
Bailly C; Denny WA; Waring MJ
Anticancer Drug Des; 1996 Dec; 11(8):611-24. PubMed ID: 9022749
[TBL] [Abstract][Full Text] [Related]
2. Sequence specificity of the binding of 9-aminoacridine- and amsacrine-4-carboxamides to DNA studied by DNase I footprinting.
Bailly C; Denny WA; Mellor LE; Wakelin LP; Waring MJ
Biochemistry; 1992 Apr; 31(13):3514-24. PubMed ID: 1554731
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, DNA-cleaving properties and cytotoxicity of intercalating chelidamic acid derivatives.
Searcey M; McClean S; Madden B; McGown AT; Wakelin LP
Anticancer Drug Des; 1998 Dec; 13(8):837-55. PubMed ID: 10335263
[TBL] [Abstract][Full Text] [Related]
4. Drug-DNA sequence-dependent interactions analysed by electric linear dichroism.
Bailly C; Hénichart JP; Colson P; Houssier C
J Mol Recognit; 1992 Dec; 5(4):155-71. PubMed ID: 1339484
[TBL] [Abstract][Full Text] [Related]
5. Copper-dependent oxidative and topoisomerase II-mediated DNA cleavage by a netropsin/4'-(9-acridinylamino)methanesulfon-m-anisidide combilexin.
Henichart JP; Waring MJ; Riou JF; Denny WA; Bailly C
Mol Pharmacol; 1997 Mar; 51(3):448-61. PubMed ID: 9058600
[TBL] [Abstract][Full Text] [Related]
6. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
[TBL] [Abstract][Full Text] [Related]
7. Interaction of a DNA-threading netropsin-amsacrine combilexin with DNA and chromatin.
Bourdouxhe-Housiaux C; Colson P; Houssier C; Waring MJ; Bailly C
Biochemistry; 1996 Apr; 35(14):4251-64. PubMed ID: 8605173
[TBL] [Abstract][Full Text] [Related]
8. [Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1' substitute on the aniline nucleus].
René B; Fossé P; Khélifa T; Jacquemin-Sablon A; Bailly C
Bull Cancer; 1997 Oct; 84(10):941-8. PubMed ID: 9435795
[TBL] [Abstract][Full Text] [Related]
9. DNA sequence recognition by bispyrazinonaphthalimides antitumor agents.
Carrasco C; Joubert A; Tardy C; Maestre N; Cacho M; Braña MF; Bailly C
Biochemistry; 2003 Oct; 42(40):11751-61. PubMed ID: 14529286
[TBL] [Abstract][Full Text] [Related]
10. Amsacrine analogues with extended chromophores: DNA binding and anti-tumour activity.
Denny WA; Baguley BC
Anticancer Drug Des; 1987 Aug; 2(1):61-70. PubMed ID: 3449085
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the topoisomerase II poison 9-amino-[N-(2-dimethylamino)ethyl]acridine-4-carboxamide bound to the DNA hexanucleotide d(CGTACG)2.
Adams A; Guss JM; Collyer CA; Denny WA; Wakelin LP
Biochemistry; 1999 Jul; 38(29):9221-33. PubMed ID: 10413496
[TBL] [Abstract][Full Text] [Related]
12. 'Minimal' DNA-intercalating agents as anti-tumour drugs: 2-styrylquinoline analogues of amsacrine.
Denny WA; Atwell GJ; Baguley BC
Anticancer Drug Des; 1987 Dec; 2(3):263-70. PubMed ID: 3449090
[TBL] [Abstract][Full Text] [Related]
13. Design of composite drug molecules: mutual effects on binding to DNA of an intercalator, amsacrine, and a minor groove binder, netropsin.
Bourdouxhe C; Colson P; Houssier C; Hénichart JP; Waring MJ; Denny WA; Bailly C
Anticancer Drug Des; 1995 Mar; 10(2):131-54. PubMed ID: 7710635
[TBL] [Abstract][Full Text] [Related]
14. The influence of the exocyclic amino group characteristic of GC base pairs on molecular recognition of specific nucleotide sequences in DNA by berenil and DAPI.
Waring MJ; Bailly C
J Mol Recognit; 1997; 10(3):121-7. PubMed ID: 9408827
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Finlay GJ; Atwell GJ; Baguley BC
Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
[TBL] [Abstract][Full Text] [Related]
16. Relationships between topoisomerase II inhibition, sequence-specificity and DNA binding mode of dicationic diphenylfuran derivatives.
Bailly C; Dassonneville L; Carrasco C; Lucas D; Kumar A; Boykin DW; Wilson WD
Anticancer Drug Des; 1999 Feb; 14(1):47-60. PubMed ID: 10363027
[TBL] [Abstract][Full Text] [Related]
17. A molecular modeling study of B-DNA-intercalation complexes with amsacrine and related 9-anilino-acridines.
Fischer G; Pindur U
Pharmazie; 1999 Feb; 54(2):83-93. PubMed ID: 10084153
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic action and cell cycle effects of ALGA, a peptidic derivative of the antileukemic drug amsacrine.
Collyn-d'Hooghe M; Bernier JL; Henichart JP
Cancer Biochem Biophys; 1987 Sep; 9(3):257-64. PubMed ID: 3435897
[TBL] [Abstract][Full Text] [Related]
19. A model for the T-antigen-induced structural alteration of the SV40 replication origin based upon experiments with specific probes for bent, straight, and unwound DNA.
Han FX; Hurley LH
Biochemistry; 1996 Jun; 35(24):7993-8001. PubMed ID: 8672503
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide.
Woynarowski JM; McCarthy K; Reynolds B; Beerman TA; Denny WA
Anticancer Drug Des; 1994 Feb; 9(1):9-24. PubMed ID: 8141968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
